Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

enVVeno Medical Corporation - Common Stock (NQ:NVNO)

4.850 -0.030 (-0.61%)
Streaming Delayed Price Updated: 12:57 PM EDT, Aug 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 41,051
Open 4.890
Bid (Size) 4.770 (2)
Ask (Size) 4.990 (3)
Prev. Close 4.880
Today's Range 4.730 - 4.950
52wk Range 2.028 - 5.810
Shares Outstanding 19,247,141
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency
Via ACCESS Newswire
enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company
Via ACCESS Newswire

Performance

YTD
+58.0%
+58.0%
1 Month
+23.4%
+23.4%
3 Month
+39.0%
+39.0%
6 Month
+48.8%
+48.8%
1 Year
-4.0%
-4.0%

More News

Read More
enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire
enVVeno Medical Participates in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference
Via ACCESS Newswire
JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live
Via ACCESS Newswire
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Via ACCESS Newswire
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe
Via ACCESSWIRE
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website
Via ACCESSWIRE
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
Via ACCESS Newswire
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
Via ACCESS Newswire
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium
Via ACCESSWIRE
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval
Via ACCESSWIRE
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
Via ACCESS Newswire
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
Via ACCESS Newswire
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Liberty Energy Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
Via ACCESS Newswire
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
Via ACCESS Newswire
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25
Via ACCESS Newswire
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
Via ACCESS Newswire
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Via ACCESS Newswire
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year
Via ACCESSWIRE

Frequently Asked Questions

Is enVVeno Medical Corporation - Common Stock publicly traded?
Yes, enVVeno Medical Corporation - Common Stock is publicly traded.
What exchange does enVVeno Medical Corporation - Common Stock trade on?
enVVeno Medical Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for enVVeno Medical Corporation - Common Stock?
The ticker symbol for enVVeno Medical Corporation - Common Stock is NVNO on the Nasdaq Stock Market
What is the current price of enVVeno Medical Corporation - Common Stock?
The current price of enVVeno Medical Corporation - Common Stock is 4.850
When was enVVeno Medical Corporation - Common Stock last traded?
The last trade of enVVeno Medical Corporation - Common Stock was at 08/06/25 12:57 PM ET
What is the market capitalization of enVVeno Medical Corporation - Common Stock?
The market capitalization of enVVeno Medical Corporation - Common Stock is 93.35M
How many shares of enVVeno Medical Corporation - Common Stock are outstanding?
enVVeno Medical Corporation - Common Stock has 93M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.